Preventing adverse reactions in pediatric transfusions using washed platelet concentrate.
M-sol
allergic transfusion reaction
bicarbonate Ringer’s solution
febrile non-hemolytic transfusion reaction
platelet additive solution
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
07
11
2020
accepted:
02
12
2020
pubmed:
9
12
2020
medline:
19
8
2021
entrez:
8
12
2020
Statut:
ppublish
Résumé
Blood transfusion is an important form of supportive care in children; however, transfusion-associated adverse reactions (TARs) are a problem. As with adults, allergic transfusion reactions (ATRs) and febrile non-hemolytic transfusion reactions (FNHTRs) are major TARs, and the frequency of ATRs caused by platelet concentrate (PC) tends to be particularly high. The plasma component of the blood product is thought to be a major factor in the onset of TARs such as ATR and FNHTR. By contrast, in children, age, underlying disease, and number of blood transfusions may be relevant patient-related factors. Although acetaminophen or diphenhydramine may be used prophylactically to prevent TARs, there is no clear evidence of their effectiveness. Volume-reduced PC is used to prevent TARs; however, it may be difficult to maintain the quality of platelets. Plasma-replaced PC stored with platelet additive solution raises the concern that TARs cannot be completely prevented by residual plasma. Washed PC removes most of the plasma, so it can effectively prevent ATR and FNHTR. The recent development of platelet additive solution [M-sol, bicarbonate Ringer's solution supplemented with acid-citrate-dextrose formula A (BRS-A)] in Japan has enabled the maintenance of the quality of platelets for long periods. The clinical use of washed PC in Japan has therefore progressed. Washed PC with M-sol or BRS-A for pediatric patients can effectively prevent TARs without diminishing the transfusion effect. The supply of washed PC has begun from the Japanese Red Cross Society, and it has become possible to use washed PC at all medical institutions in Japan.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-403Informations de copyright
© 2020 Japan Pediatric Society.
Références
Gauvin F, Lacroix J, Robillard P, Lapointe H, Hume H. Acute transfusion reactions in the pediatric intensive care unit. Transfusion 2006; 46: 1899-908.
Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. Paediatr. Anaesth. 2011; 21: 14-24.
Li N, Williams L, Zhou Z, Wu Y. Incidence of acute transfusion reactions to platelets in hospitalized pediatric patients based on the US hemovigilance reporting system. Transfusion 2014; 54: 1666-72.
Moncharmont P. Adverse transfusion reactions in transfused children. Transfus. Clin. Biol. 2019; 26: 329-35.
Oakley FD, Woods M, Arnold S, Young PP. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion 2015; 55: 563-70.
Vossoughi S, Perez G, Whitaker BI, Fung MK, Stotler B. Analysis of pediatric adverse reactions to transfusions. Transfusion 2018; 58: 60-69.
Brand A. Immunological aspects of blood transfusions. Blood Rev. 2000; 14: 130-44.
Ogedegbe H. A review of non-immune mediated transfusion reactions. Lab. Med. 2002; 33: 380-5.
Ogedegbe H. A review of immune mediated transfusion reactions. Lab. Med. 2002; 33: 287-95.
Savage WJ. Transfusion reactions. Hematol. Oncol. Clin. North Am. 2016; 30: 619-34.
Hirayama F. Recent advances in laboratory assays for nonhemolytic transfusion reactions. Transfusion 2010; 50: 252-63.
Keir AK, New H, Robitaille N, Crighton GL, Wood EM, Stanworth SJ. Approaches to understanding and interpreting the risks of red blood cell transfusion in neonates. Transfus. Med. 2019; 29: 231-38.
Stainsby D, Jones H, Wells AW, Gibson B, Cohen H. Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996-2005. Br. J. Haematol. 2008; 141: 73-9.
De Pascale MR, Belsito A, Sommese L et al. Blood transfusions and adverse acute events: a retrospective study from 214 transfusion-dependent pediatric patients comparing transfused blood components by apheresis or by whole blood. Ann. Ist. Super. Sanita. 2019; 55: 351-56.
Yanagisawa R, Shimodaira S, Sakashita K et al. Factors related to allergic transfusion reactions and febrile non-haemolytic transfusion reactions in children. Vox Sang. 2016; 110: 376-84.
Berg A, Courtney R, Krishnamurti L, Triulzi DJ, Yazer MH. Is intensive monitoring during the first transfusion in pediatric patients necessary? Hematology. 2014; 19: 304-8.
Pedrosa AK, Pinto FJ, Lins LD, Deus GM. Blood transfusion reactions in children: associated factors. J. Pediatr. (Rio J.). 2013; 89: 400-6.
Slonim AD, Joseph JG, Turenne WM, Sharangpani A, Luban NL. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008; 48: 73-80.
Couban S, Carruthers J, Andreou P et al. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion 2002; 42: 753-8.
Sanders RP, Maddirala SD, Geiger TL et al. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br. J. Haematol. 2005; 130: 781-7.
Trakhtman P, Karpova O, Balashov D et al. Efficacy and safety of pathogen-reduced platelet concentrates in children with cancer: a retrospective cohort study. Transfusion 2016; 56(Suppl 1): S24-8.
Schulz WL, McPadden J, Gehrie EA et al. Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets. J. Pediatr. 2019; 209: 220-25.
Trakhtman P, Kumukova I, Starostin N et al. The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases. Vox Sang. 2019; 114: 223-31.
Hu W, Feng L, Li M, Li T, Dai Y, Wang X. Platelet concentrate and type II IL-1 receptor are risk factors for allergic transfusion reactions in children. Ital. J. Pediatr. 2020; 46: 109.
Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood 2019; 133: 1831-39.
Chen J, Biller E, Losos M et al. Irradiation and prolonged storage of red cells are associated with increased adverse events. Vox Sang 2018; 113: 468-75.
Yanagisawa R, Tatsuzawa Y, Ono T et al. Analysis of clinical presentations of allergic transfusion reactions and febrile non-haemolytic transfusion reactions in paediatric patients. Vox Sang. 2019; 114: 826-34.
Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br. J. Haematol. 2013; 160: 434-44.
Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus. Med. Rev. 2007; 21: 1-12.
Hirayama F. Approach of using established and new laboratory tests to more comprehensively investigate noninfectious and nonhemolytic transfusion reactions-along with the experience in Japan. Vox Sang. 2013; 105: 183-95.
Hendrickson JE, Roubinian NH, Chowdhury D et al. Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion 2016; 56: 2587-96.
Yanagisawa R, Fujihara I, Komori K et al. Transfusion-associated circulatory overload in a pediatric patient with neuroblastoma. Transfus. Apher. Sci. 2017; 56: 445-47.
Yanagisawa R, Abe S, Fujihara I et al. Transfusion-associated hypoxemia in pediatric patients with solid tumors after autologous peripheral blood stem cell transplantation. Transfus. Apher. Sci. 2017; 56: 744-47.
Fanaro S. Blood transfusion in infants: techniques and adverse events. J. Matern. Fetal Neonatal Med. 2011; 24(Suppl 1): 47-9.
Holman P, Blajchman MA, Heddle N. Noninfectious adverse effects of blood transfusion in the neonate. Transfus. Med. Rev. 1995; 9: 277-87.
Zhu Z, Hua X, Yu Y, Zhu P, Hong K, Ke Y. Effect of red blood cell transfusion on the development of retinopathy of prematurity: A systematic review and meta-analysis. PLoS One 2020; 15: e0234266.
Patel RM, Knezevic A, Shenvi N et al. Association of red blood cell transfusion, anemia, and necrotizing enterocolitis in very low-birth-weight infants. JAMA 2016; 315: 889-97.
Delaney M, Wendel S, Bercovitz RS et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet 2016; 388: 2825-36.
Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr. Opin. Hematol. 1999; 6: 420-6.
Cohen R, Escorcia A, Tasmin F et al. Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions. Transfusion 2017; 57: 1674-83.
Sandler SG. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion 2006; 46: 10-3.
Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus. Med. Rev. 1995; 9: 1-8.
Koda Y, Watanabe Y, Soejima M et al. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000; 95: 1138-43.
Shimada E, Tadokoro K, Watanabe Y et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002; 42: 766-73.
Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J. Lab. Clin. Med. 1995; 125: 348-55.
Lambin P, Le Pennec PY, Hauptmann G, Desaint O, Habibi B, Salmon C. Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specificity. Vox Sang. 1984; 47: 242-9.
Westhoff CM, Sipherd BD, Wylie DE, Toalson LD. Severe anaphylactic reactions following transfusions of platelets to a patient with anti-Ch. Transfusion 1992; 32: 576-9.
Jacobs JF, Baumert JL, Brons PP, Joosten I, Koppelman SJ, van Pampus EC. Anaphylaxis from passive transfer of peanut allergen in a blood product. N. Engl. J. Med. 2011; 364: 1981-2.
Michel J, Sharon R. Non-haemolytic adverse reaction after transfusion of a blood unit containing penicillin. Br. Med. J. 1980; 280: 152-3.
Nubret K, Delhoume M, Orsel I, Laudy JS, Sellami M, Nathan N. Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011; 51: 125-8.
Poothullil J, Shimizu A, Day RP, Dolovich J. Anaphylaxis from the product(s) of ethylene oxide gas. Ann. Intern. Med. 1975; 82: 58-60.
Maurice F, Rivory JP, Larsson PH, Johansson SG, Bousquet J. Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis. J. Allergy Clin. Immunol. 1986; 77: 594-7.
Arnold DM, Blajchman MA, Ditomasso J, Kulczycki M, Keith PK. Passive transfer of peanut hypersensitivity by fresh frozen plasma. Arch Intern Med. 2007; 167: 853-4.
Heddle NM, Klama L, Singer J et al. The role of the plasma from platelet concentrates in transfusion reactions. N. Engl. J. Med. 1994; 331: 625-8.
Tobian AA, Savage WJ, Tisch DJ, Thoman S, King KE, Ness PM. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011; 51: 1676-83.
Heddle NM, Klama L, Meyer R et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39: 231-8.
Yasui K, Matsuyama N, Takihara Y, Hirayama F. New insights into allergic transfusion reactions and their causal relationships, pathogenesis, and prevention. Transfusion 2020; 60: 1590-601.
Kluter H, Bubel S, Kirchner H, Wilhelm D. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999; 39: 1179-84.
Blumberg N, Gettings KF, Turner C, Heal JM, Phipps RP. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46: 1813-21.
Nguyen KA, Hamzeh-Cognasse H, Sebban M et al. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes. PLoS One 2014; 9: e97082.
Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33: 794-7.
Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195-9.
Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001; 357: 2023-4.
Vo TD, Cowles J, Heal JM, Blumberg N. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus. Med. 2001; 11: 45-7.
Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44: 16-24.
Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44: 10-5.
King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44: 25-9.
Shanwell A, Kristiansson M, Remberger M, Ringden O. Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion 1997; 37: 678-84.
Savage WJ, Tobian AA, Savage JH, Wood RA, Schroeder JT, Ness PM. Scratching the surface of allergic transfusion reactions. Transfusion 2013; 53: 1361-71.
Azuma H, Hirayama J, Akino M et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49: 214-8.
Okamura I, Matsuyama N, Yasui K, Hirayama F, Ikeda T. Clinical utility of the basophil activation test for analysis of allergic transfusion reactions: a pilot study. Vox Sang. 2017; 112: 114-21.
Kasim J, Aldarweesh F, Connor JP. Blood product and laboratory resource wastage in non-severe allergic transfusion reactions: an opportunity for improvement. Transfus. Med. 2019; 29: 338-43.
Savage WJ, Tobian AA, Savage JH, Hamilton RG, Ness PM. Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets. Transfusion 2011; 51: 2337-42.
Savage WJ, Hamilton RG, Tobian AA et al. Defining risk factors and presentations of allergic reactions to platelet transfusion. J. Allergy. Clin. Immunol. 2014; 133: 1772-5. e9.
Ide Y, Yanagisawa R, Kobayashi J et al. Relationship between allergic sensitization-associated single-nucleotide polymorphisms and allergic transfusion reactions and febrile nonhemolytic transfusion reactions in pediatric cases. Blood Transfus. 2020. In press.
Menis M, Forshee RA, Anderson SA et al. Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012. Vox Sang. 2015; 108: 251-61.
Addas-Carvalho M, Salles TS, Saad ST. The association of cytokine gene polymorphisms with febrile non-hemolytic transfusion reaction in multitransfused patients. Transfus. Med. 2006; 16: 184-91.
Chen DP, Wen YH, Lu JJ, Tseng CP, Chen WL, Chang SW. Human platelet antigens are associated with febrile non-hemolytic transfusion reactions. Clin. Chim. Acta. 2017; 474: 120-23.
Tinegate H, Birchall J, Gray A et al. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force. Br. J. Haematol. 2012; 159: 143-53.
Ezidiegwu CN, Lauenstein KJ, Rosales LG, Kelly KC, Henry JB. Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch. Pathol. Lab. Med. 2004; 128: 991-5.
Saito S, Yanagisawa R, Minami K et al. Prophylactic piperacillin administration in pediatric patients with solid tumors following different intensities of chemotherapy. Pediatr. Int. 2020; 62: 158-68.
Liaw CC, Huang JS, Chen JS, Chang JW, Chang HK, Liau CT. Using vital sign flow sheets can help to identify neoplastic fever and other possible causes in oncology patients: a retrospective observational study. J. Pain Symptom Manage. 2010; 40: 256-65.
Murphy MF, Atterbury CLJ, Chapman JF et al. The administration of blood and blood components and the management of transfused patients. British Committee for Standards in Haematology, Blood Transfusion Task Force. Royal College of Nursing and the Royal College of Surgeons of England. Transfus. Med. 1999; 9: 227-38.
Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion 2008; 48: 2285-91.
Wang SE, Lara PN Jr, Lee-Ow A et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am. J. Hematol. 2002; 70: 191-4.
Fry JL, Arnold DM, Clase CM et al. Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices. Transfusion 2010; 50: 1722-30.
Yanagisawa R, Shimodaira S, Kojima S et al. Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients. Transfusion 2013; 53: 2053-60.
Nellis ME, Goel R, Karam O. Transfusion management in pediatric oncology patients. Hematol. Oncol. Clin. North. Am. 2019; 33: 903-13.
van der Meer PF, Bontekoe IJ, Kruit G et al. Volume-reduced platelet concentrates: optimization of production and storage conditions. Transfusion 2012; 52: 819-27.
Honohan A, Tomson B, van der Bom J, de Vries R, Brand A. A comparison of volume-reduced versus standard HLA/HPA-matched apheresis platelets in alloimmunized adult patients. Transfusion 2012; 52: 742-51.
Veeraputhiran M, Ware J, Dent J et al. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion 2011; 51: 1030-6.
Schoenfeld H, Spies C, Jakob C. Volume-reduced platelet concentrates. Curr. Hematol. Rep. 2006; 5: 82-8.
van der Meer PF, de Korte D. Platelet additive solutions: a review of the latest developments and their clinical implications. Transfus. Med. Hemother. 2018; 45: 98-102.
de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000; 40: 398-403.
Cohn CS, Stubbs J, Schwartz J et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 2014; 54: 1927-34.
Tobian AA, Fuller AK, Uglik K et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014; 54: 1523-9.
Oikawa S, Minegishi M, Endo K, Kawashima W, Suzuki K, Shimizu H. In vitro analysis of volume-reduced washed platelet concentrates stored in bicarbonated Ringer's solution containing less than 5% residual plasma. Vox Sang. 2016; 111: 16-21.
Schoenfeld H, Muhm M, Doepfmer UR, Kox WJ, Spies C, Radtke H. The functional integrity of platelets in volume-reduced platelet concentrates. Anesth. Analg. 2005; 100: 78-81.
Schiffer CA, Bohlke K, Delaney M et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 2018; 36: 283-99.
Tanaka M, Yanagisawa R, Yamanaka M et al. Transfusion outcome for volume- and plasma-reduced platelet concentrates for pediatric patients. Transfus. Apher. Sci. 2020; 59: 102776.
Smogorzewska A, Dzik W. Transfusion medicine illustrated. Volume-reduced apheresis platelets. Transfusion 2005; 45: 651.
Jacquot C, Mo YD, Luban NLC. New approaches and trials in pediatric transfusion medicine. Hematol. Oncol. Clin. North Am. 2019; 33: 507-20.
Gulliksson H. Platelet storage media. Vox Sang. 2014; 107: 205-12.
Buck SA, Kickler TS, McGuire M, Braine HG, Ness PM. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987; 27: 391-3.
Azuma H, Ikeda H. Washed/replaced (W/R)-platelets. ISBT Sci. Ser. 2009; 4: 342-6.
Kobayashi J, Yanagisawa R, Ono T et al. Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions. Vox Sang. 2018; 113: 128-35.
Hirayama J, Azuma H, Fujihara M, Homma C, Yamamoto S, Ikeda H. Storage of platelets in a novel additive solution (M-sol), which is prepared by mixing solutions approved for clinical use that are not especially for platelet storage. Transfusion 2007; 47: 960-5.
Hirayama J, Azuma H, Fujihara M et al. Comparison between in vitro qualities of platelets washed with commercially available additive solutions and those washed with M-sol. Vox Sang. 2010; 99: 131-5.
de Wildt-Eggen J, Schrijver JG, Bins M, Gulliksson H. Storage of platelets in additive solutions: effects of magnesium and/or potassium. Transfusion 2002; 42: 76-80.
Azuma H, Hirayama J, Akino M, Ikeda H. Platelet additive solution - electrolytes. Transfus. Apher. Sci. 2011; 44: 277-81.
Oikawa S, Sasaki D, Kikuchi M, Sawamura Y, Itoh T. Comparative in vitro evaluation of apheresis platelets stored with 100% plasma versus bicarbonated Ringer's solution with less than 5% plasma. Transfusion 2013; 53: 655-60.
Oikawa S, Taguchi T, Endo K et al. Storage of washed platelets in BRS-A platelet additive solutions based on two types of clinically available bicarbonated Ringer's solutions with different electrolyte concentrations. Transfus. Apher. Sci. 2015; 53: 233-7.
Iwama A, Hirayama J, Nogawa M et al. Comparison between in vitro properties of washed platelet concentrates suspended in M-sol and those in BRS-A, both of which were prepared with an automated cell processor. Transfus. Apher. Sci. 2017; 56: 241-44.
Kojima S, Yanagisawa R, Tanaka M, Nakazawa Y, Shimodaira S. Comparison of administration of platelet concentrates suspended in M-sol or BRS-A for pediatric patients. Transfusion 2018; 58: 2952-58.
Karafin M, Fuller AK, Savage WJ, King KE, Ness PM, Tobian AA. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012; 52: 1221-7.
Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002; 42: 1398-413.
Hirayama J, Fujihara M, Akino M et al. Storage of volume-reduced washed platelets in M-sol additive solution for 7 days. Transfusion 2014; 54: 3173-7.
Oikawa S, Sasaki D, Kikuchi M, Sawamura Y, Itoh T. Feasibility of a closed-system cell processor (ACP215) for automated preparation of washed platelet concentrates. Vox Sang. 2012; 102: 110-5.
Oikawa S, Minegishi M, Endo K, Kawashima W, Suzuki K, Shimizu H. Washing of platelets can be fully automated using a closed-system cell processor and BRS-A platelet additive solution. Vox Sang. 2016; 111: 437-40.
Oikawa S, Minegishi M, Endo K et al. Impact of the platelet washing process on in vitro platelet properties, and the levels of soluble CD40 ligand and platelet-derived microparticles in the storage media. Transfusion 2019; 59: 1080-89.
Fujiwara SI, Fujishima N, Kanamori H et al. Released washed platelet concentrates are effective and safe in patients with a history of transfusion reactions. Transfus Apher Sci. 2018; 57: 746-51.
Ikebe E, Matsuoka S, Tanaka A et al. Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan-A retrospective multicenter study. Transfus Apher Sci. 2019; 58: 162-68.
Berseus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion 2013; 53(Suppl 1): 114S-23S.
Adkins BD, Lawicki S, Johnson M, Eichbaum Q. Mild allergic transfusion reactions: Impact of associated clinical symptoms? Am J Clin Pathol. 2019; 151: 344-48.
Dasararaju R, Marques MB. Adverse effects of transfusion. Cancer Control. 2015; 22: 16-25.
Satake M, Mitani T, Oikawa S et al. Frequency of bacterial contamination of platelet concentrates before and after introduction of diversion method in Japan. Transfusion 2009; 49: 2152-7.
Hirayama J, Azuma H, Fujihara M et al. Comparison between bacterial growth in platelets (PLTs) washed with M-sol and that in PLT-rich plasma. Transfusion 2011; 51: 1592-4.